Cases & Deals

  • Home
  • Practices
  • Incyte enters strategic collaboration agreement with Innovent for three clinical pharmaceuticals in China

Share

Incyte enters strategic collaboration agreement with Innovent for three clinical pharmaceuticals in China

December 2018

Client(s) Incyte Corporation

Jones Day represented Incyte Pharmaceuticals in its strategic collaboration and license agreement with Innovent Biologics for the regulatory development and commercialization in China of three clinical stage pharmaceutical candidates, a FGFR1/2/3 inhibitor, a JAK1 inhibitor, and a PI3K delta inhibitor, for treatment of hematological and oncological diseases. Innovent pays a $40 million upfront fee to Incyte, and Incyte is entitled to receive future development milestones totaling up to $129 million and commercialization milestones totaling up to $202.5 million plus tiered royalties. Incyte is entitled to co-promote each of the commercial products with Innovent.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.